All type of patients: 1 trials - ATTRACTION-2
| nivolumab vs placebo | No demonstrated result suggested death (overall survival) by 37% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | 0.63 [0.51 0.78] | p=0.04 | 0 | 493 | 1 | ATTRACTION-2, | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - Checkmate-141 - Checkmate-651
| nivolumab vs standard treatment | death (overall survival) by 30% (fully demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | 0.70 [0.51 0.96] | p=0.04 | 0 | 361 | 1 | Checkmate-141, | | progression or death (progression free survival PFS) | 0.89 [0.70 1.13] | p=1.00 | 0 | 361 | 1 | Checkmate-141, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilumab vs standard treatment | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 9 trials - CheckMate 057 - CheckMate 153 - CheckMate 026 - CheckMate 017 - Checkmate 032 - CheckMate 078 - CheckMate 227 (High Tumor Mutational Burden) - CheckMate 227 (nivolumab alone) - CheckMate 227 (nivolumab + CT)
| nivolumab vs docetaxel | No demonstrated result suggested objective response (ORR) by 128% (not demonstrated) suggested Grade 3–5 drug-related AEs by 83% (not demonstrated) suggested death (overall survival) by 32% (not demonstrated) suggested progression or death (progression free survival PFS) by 18% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | 2.28 [1.10 4.72] | p=0.04 | 0 | 272 | 1 | CheckMate 017, | | Grade 3–5 drug-related AEs | 0.17 [0.12 0.26] | p=0.04 | 0 | 815 | 2 | CheckMate 057,CheckMate 017, | | death (overall survival) | 0.68 [0.57 0.81] | p=0.04 | 0 | 854 | 2 | CheckMate 057,CheckMate 017, | | progression or death (progression free survival PFS) | 0.82 [0.70 0.95] | p=0.04 | 0 | 854 | 2 | CheckMate 057,CheckMate 017, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab vs platinum-based CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | 1.02 [0.80 1.30] | p=1.00 | 0 | 541 | 1 | CheckMate 026, | | progression or death (progression free survival PFS) | 1.15 [0.91 1.45] | p=1.00 | 0 | 541 | 1 | CheckMate 026, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + CT vs platinum-based CT | No demonstrated result suggested progression or death (progression free survival PFS) by 26% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.74 [0.58 0.94] | p=0.04 | 0 | 363 | 1 | CheckMate 227 (nivolumab + CT), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs nivolumab | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs platinum-based CT | No demonstrated result suggested progression or death (progression free survival PFS) by 42% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.58 [0.41 0.82] | p=0.04 | 0 | 299 | 1 | CheckMate 227 (High Tumor Mutational Burden), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab for 1 year vs nivolumab | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
First line: 4 trials - CheckMate 026 - CheckMate 227 (High Tumor Mutational Burden) - CheckMate 227 (nivolumab alone) - CheckMate 227 (nivolumab + CT)
| nivolumab vs platinum-based CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | 1.02 [0.80 1.30] | p=1.00 | 0 | 541 | 1 | CheckMate 026, | | progression or death (progression free survival PFS) | 1.15 [0.91 1.45] | p=1.00 | 0 | 541 | 1 | CheckMate 026, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + CT vs platinum-based CT | No demonstrated result suggested progression or death (progression free survival PFS) by 26% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.74 [0.58 0.94] | p=0.04 | 0 | 363 | 1 | CheckMate 227 (nivolumab + CT), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs platinum-based CT | No demonstrated result suggested progression or death (progression free survival PFS) by 42% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.58 [0.41 0.82] | p=0.04 | 0 | 299 | 1 | CheckMate 227 (High Tumor Mutational Burden), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Second line : 8 trials - CheckMate 057 - CheckMate 153 - CheckMate 017 - Checkmate 032 - CheckMate 078 - CheckMate 451 - CheckMate 331 - CheckMate 722
| nivolumab vs CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab vs docetaxel | No demonstrated result suggested objective response (ORR) by 128% (not demonstrated) suggested Grade 3–5 drug-related AEs by 83% (not demonstrated) suggested death (overall survival) by 32% (not demonstrated) suggested progression or death (progression free survival PFS) by 18% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | 2.28 [1.10 4.72] | p=0.04 | 0 | 272 | 1 | CheckMate 017, | | Grade 3–5 drug-related AEs | 0.17 [0.12 0.26] | p=0.04 | 0 | 815 | 2 | CheckMate 057,CheckMate 017, | | death (overall survival) | 0.68 [0.57 0.81] | p=0.04 | 0 | 854 | 2 | CheckMate 057,CheckMate 017, | | progression or death (progression free survival PFS) | 0.82 [0.70 0.95] | p=0.04 | 0 | 854 | 2 | CheckMate 057,CheckMate 017, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs nivolumab | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs platinum-based CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab for 1 year vs nivolumab | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Adjuvant 1 - NOVARTIS: 1 trials - CheckMate 238
Adjuvant setting: 1 trials - CheckMate 238
Adjuvant stage III only - NOVARTIS : 1 trials - CheckMate 238 subgroup IIIB-C
| nivolumab vs ipilimumab | No demonstrated result suggested recurrence free survival by 35% (not demonstrated) suggested distant metastasis free survival by 27% (not demonstrated) suggested progression or death (progression free survival PFS) by 35% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | recurrence free survival | 0.65 [0.51 0.82] | p=0.04 | 0 | -18 | 1 | CheckMate 238 subgroup IIIB-C, | | distant metastasis free survival | 0.73 [0.56 0.96] | p=0.04 | 0 | -18 | 1 | CheckMate 238 subgroup IIIB-C, | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.65 [0.51 0.82] | p=0.04 | 0 | -18 | 1 | CheckMate 238 subgroup IIIB-C, | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 7 trials - CheckMate 067 (nivo + ipi vs ipi) - CheckMate 066 (Robert) - CheckMate 037 (Weber) - CheckMate 238 - Postow - CheckMate 067 (nivo vs ipi) - CheckMate 067 (nivo + ipi vs nivo)
| nivolumab vs chemotherapy | No demonstrated result suggested objective response (ORR) by 272% (not demonstrated) suggested Grade 3–5 drug-related AEs by 71% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | 3.72 [1.25 11.12] | p=0.04 | 0 | 167 | 1 | CheckMate 037 (Weber), | | Grade 3–5 drug-related AEs | 0.29 [0.16 0.52] | p=0.04 | 0 | 370 | 1 | CheckMate 037 (Weber), | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab vs dacarbazine | death (overall survival) by 58% (fully demonstrated) vitiligo any grade by 2089% (harmful effect) suggested progression or death (progression free survival PFS) by 57% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 0.66 [0.38 1.16] | p=1.00 | 0 | 411 | 1 | CheckMate 066 (Robert), | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | 0.42 [0.25 0.71] | p=0.04 | 0 | 418 | 1 | CheckMate 066 (Robert), | | progression or death (progression free survival PFS) | 0.43 [0.34 0.55] | p=0.04 | 0 | 418 | 1 | CheckMate 066 (Robert), | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | 21.89 [2.92 164.04] | p=0.04 | 0 | 411 | 1 | CheckMate 066 (Robert), | | vitiligo grade 3-4 | 1.00 [0.02 50.40] | p=1.00 | 0 | 411 | 1 | CheckMate 066 (Robert), | | Adverse events leading to treatment discontinuation | 0.58 [0.29 1.16] | p=1.00 | 0 | 411 | 1 | CheckMate 066 (Robert), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab vs ipilimumab | recurrence free survival by 35% (fully demonstrated) progression or death (progression free survival PFS) by 39% (fully demonstrated) suggested Grade 3–5 drug-related AEs by 59% (not demonstrated) suggested Adverse events leading to treatment discontinuation by 70% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 0.41 [0.32 0.52] | p=0.04 | 0 | 1529 | 2 | CheckMate 238,CheckMate 067 (nivo vs ipi), | | recurrence free survival | 0.65 [0.51 0.83] | p=0.04 | 0 | 906 | 1 | CheckMate 238, | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.61 [0.51 0.74] | p=0.04 | 0 | 1537 | 2 | CheckMate 238,CheckMate 067 (nivo vs ipi), | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | 0.30 [0.22 0.40] | p=0.04 | 0 | 1530 | 2 | CheckMate 238,CheckMate 067 (nivo vs ipi), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs ipilimumab | progression or death (progression free survival PFS) by 58% (fully demonstrated) Adverse events leading to treatment discontinuation by 146% (harmful effect) suggested Grade 3–5 drug-related AEs by 101% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 2.01 [1.44 2.81] | p=0.04 | 0 | 624 | 1 | CheckMate 067 (nivo + ipi vs ipi), | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.42 [0.31 0.57] | p=0.04 | 0 | 629 | 1 | CheckMate 067 (nivo + ipi vs ipi), | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | 2.46 [1.67 3.63] | p=0.04 | 0 | 624 | 1 | CheckMate 067 (nivo + ipi vs ipi), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs nivolumab | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
First line : 4 trials - CheckMate 067 (nivo + ipi vs ipi) - CheckMate 066 (Robert) - CheckMate 067 (nivo vs ipi) - CheckMate 067 (nivo + ipi vs nivo)
| nivolumab vs dacarbazine | death (overall survival) by 58% (fully demonstrated) vitiligo any grade by 2089% (harmful effect) suggested progression or death (progression free survival PFS) by 57% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 0.66 [0.38 1.16] | p=1.00 | 0 | 411 | 1 | CheckMate 066 (Robert), | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | 0.42 [0.25 0.71] | p=0.04 | 0 | 418 | 1 | CheckMate 066 (Robert), | | progression or death (progression free survival PFS) | 0.43 [0.34 0.55] | p=0.04 | 0 | 418 | 1 | CheckMate 066 (Robert), | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | 21.89 [2.92 164.04] | p=0.04 | 0 | 411 | 1 | CheckMate 066 (Robert), | | vitiligo grade 3-4 | 1.00 [0.02 50.40] | p=1.00 | 0 | 411 | 1 | CheckMate 066 (Robert), | | Adverse events leading to treatment discontinuation | 0.58 [0.29 1.16] | p=1.00 | 0 | 411 | 1 | CheckMate 066 (Robert), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab vs ipilimumab | progression or death (progression free survival PFS) by 43% (fully demonstrated) suggested Grade 3–5 drug-related AEs by 40% (not demonstrated) suggested Adverse events leading to treatment discontinuation by 48% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 0.60 [0.40 0.88] | p=0.04 | 0 | 624 | 1 | CheckMate 067 (nivo vs ipi), | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.57 [0.43 0.76] | p=0.04 | 0 | 631 | 1 | CheckMate 067 (nivo vs ipi), | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | 0.52 [0.31 0.87] | p=0.04 | 0 | 624 | 1 | CheckMate 067 (nivo vs ipi), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs ipilimumab | progression or death (progression free survival PFS) by 58% (fully demonstrated) Adverse events leading to treatment discontinuation by 146% (harmful effect) suggested Grade 3–5 drug-related AEs by 101% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 2.01 [1.44 2.81] | p=0.04 | 0 | 624 | 1 | CheckMate 067 (nivo + ipi vs ipi), | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.42 [0.31 0.57] | p=0.04 | 0 | 629 | 1 | CheckMate 067 (nivo + ipi vs ipi), | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | 2.46 [1.67 3.63] | p=0.04 | 0 | 624 | 1 | CheckMate 067 (nivo + ipi vs ipi), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs nivolumab | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Second line (or later): 1 trials - CheckMate 037 (Weber)
| nivolumab vs chemotherapy | No demonstrated result suggested objective response (ORR) by 272% (not demonstrated) suggested Grade 3–5 drug-related AEs by 71% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | 3.72 [1.25 11.12] | p=0.04 | 0 | 167 | 1 | CheckMate 037 (Weber), | | Grade 3–5 drug-related AEs | 0.29 [0.16 0.52] | p=0.04 | 0 | 370 | 1 | CheckMate 037 (Weber), | | recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | serious drug-related adverse events | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - CheckMate 602
All type of patients: 2 trials - Chekmate 025 (Motzer) - CheckMate-214
| nivolumab vs everolimus | No demonstrated result suggested death (overall survival) by 27% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | 0.73 [0.57 0.93] | p=0.04 | 0 | -18 | 1 | Chekmate 025 (Motzer), | | progression or death (progression free survival PFS) | 0.88 [0.75 1.03] | p=1.00 | 0 | -18 | 1 | Chekmate 025 (Motzer), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + ipilimumab vs sunitinib | death (overall survival) by 32% (fully demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | 0.68 [0.49 0.95] | p=0.04 | 0 | -18 | 1 | CheckMate-214, | | progression or death (progression free survival PFS) | 0.82 [0.64 1.05] | p=1.00 | 0 | -18 | 1 | CheckMate-214, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 4 trials - CheckMate 274 - Checkmate 275 - CHECKMATE 901A - CHECKMATE 274A
| nivolumab vs nil | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | complete response (CR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | complete response (CR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nivolumab + CT vs chemotherapy | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | complete response (CR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
